It has been well demonstrated that irradiated dying cancer cells release tumor antigens. The extracellular antigens and dying tumor cells are engulfed by circulating bone marrowderived antigen-presenting cells (APCs). After antigen uptake, APCs migrate to lymph nodes, where they engage with helper T cells for post-stimulation and APC activation. Induction of Th1 response and the activation of APCs further stimulate the induction of tumor specific cytotoxic T lymphocytes (CTLs) that could potentially clear tumor cells both at primary and metastatic sites (Fig. 1) .
Radiation-induced immune modulation happens in two important phases. First, radiation induces damage-associated molecular pattern (DAMP) molecules. In this event, radiation normalizes tumor vasculature, modulates tumor cell phenotype and increases immune recognition of the tumor cell. Radiation treatment can cause: a. upregulation of chemokines and adhesion molecules, providing signals for T cells to be attracted to the tumor; and b. upregulation of MHC molecules and tumor-associated antigens, making it easier for endogenous or immunotherapy-induced T cells to recognize and kill tumor (immunogenic modulation). Second, amplification by abrogating immune checkpoint factors with simultaneous costimulation of effector factors can ultimately lead to the induction of multiple unique Tcell populations (antigen cascade) that can kill antigen disparate tumor cells at metastatic sites (systemic effect) (Fig. 2) .
Radiation-Induced Immunomodulation
This issue highlights novel findings and concepts on the immunobiology of radiation therapy coupled with translational concepts. Wattenberg et al. (4) demonstrated that autologous T-cell infusion with highdose hypofractionated radiation could compensate the lymphodepletive conditions for a more effective outcome than high-dose hypofractionated radiotherapy alone. These findings emphasize the need to combine radiation therapy with immune augmenting strategies for better outcomes. Along similar lines, there is an argument that radiation therapy alone does not have the intensity to generate enough proinflammatory signals to help overcome radiation-induced immune suppressive factors (5). Therefore, a partnership of radiation with targeted immunotherapy agents appears to be important to achieve therapeutically effective antitumor immune response and this partnership has shown some promising outcomes in preclinical and clinical settings (5).
Myeloid Cells in Radiation-Induced Immunomodulation
Macrophages and dendritic cells (DCs) play important roles in radiation-induced immune modulation. Adaptive immune response triggered by radiation therapy for tumor control can be negated by several factors activated through tumor myeloid cells (6) . One such factor is Arginase I, which was shown to have a role in improving radiationtreated tumor control, although targeting multiple pathways in macrophage differentiation maybe a more effective tumor control strategy (6) tumor-specific response (7) . In a followup study, Kawashita et al. (8) demonstrated an augmented antitumor immune response when CD40L was combined with radiationinducible gene therapy plus Adeno-Flt3L in an orthotopic tumor model of hepatocellular carcinoma (8) . Dendritic cellbased immunotherapy has shown promise in combination settings. The activation of effector DCs through radiationinduced Toll-like receptor (TLR) signaling presents a strong rationale for the potential to integrate radiotherapy with DCbased immunotherapy strategies (9).
Radiation-Induced Immunomodulation and Antigen Presentation
Crosstalk between immunomodulation and signal transduction pathways is vital when considering the use of targeted immune therapy. Verbrugge et al. (10) reported on the influence of crosstalk, and demonstrated that mTOR activity is important for achieving the efficacy of radioimmunotherapy.
Immune Therapeutics in Radiation Therapy
Recently, there has been an increase in preclinical and clinical trials with new immune agents that target the inhibition of immune checkpoint proteins and thereby augment co-immune stimulatory proteins. In this era of modern immune therapeutics, it is important to understand the biologics, for example, Almo and Guha (11) examined the parameters of how affinity, selectivity, oligomeric state and valency can play major roles when designing studies that include radiotherapy.
Immunotherapy has shown efficacy in melanoma and renal cell carcinoma, however, its role in ovarian cancer is still under investigation despite evidence that it is an immunogenic disease. Although radiotherapy is not a mainstream regimen for ovarian cancer, data suggest that it should nevertheless be investigated as a means to exploit the high immunogenicity phenotype of this disease (12) .
It is evident from the literature as well as the recent trends reported in this focus issue that radiation therapy as part of immunotherapy represents an attractive combination for clinical trials. Sharon et al. (13) provides important challenges such as preclinical design, dose/dose fractionation, overlapping toxicities, efficacy end points and statistical approaches that should be carefully addressed in the design of clinical trials.
Immunobiology of radiation therapy could contribute significantly to the treatment of aggressive solid tumors. To help advance the field, this focus issue provides scientific thinking in various facets of immuno-radiobiology, which has the potential for rapid clinical translation into novel cancer therapeutics.
